GlassScriptPhysician profile
Manjula J Naik
NPI 1760650246
$4,332.68
in general payments reported to CMS, 2019-2025
31 companies · $747 in 2025
The $747 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $899 · 2020: $182 · 2021: $325 · 2022: $776 · 2023: $806 · 2024: $598 · 2025: $747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,151.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $781.58 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $480.80 | 2019-2025 | Jynarque |
| Vifor Pharma, INC. | $392.52 | 2019-2025 | Veltassa, Korsuva |
| Amgen INC. | $347.48 | 2019-2024 | Tavneos, Parsabiv |
| Glaxosmithkline, LLC. | $225.02 | 2021-2024 | Benlysta, Jesduvroq |
| Mallinckrodt Hospital Products INC. | $214.72 | 2021-2024 | Acthar |
| Opko Pharmaceuticals, LLC | $190.31 | 2019-2025 | Rayaldee |
| Novartis Pharmaceuticals Corporation | $164.18 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $152.64 | 2022-2025 | |
| Fresenius USA Marketing, INC. | $151.83 | 2019-2025 | Velphoro |
| Mallinckrodt Enterprises LLC | $144.24 | 2019 | |
| Lilly USA, LLC | $140.79 | 2023-2025 | Jardiance, Zepbound, Mounjaro |
| Akebia Therapeutics INC | $135.35 | 2019-2025 | Vafseo |
| Travere Therapeutics, INC. | $96.75 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $93.70 | 2019-2025 | Ultomiris |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $91.54 | 2019-2022 | |
| Calliditas Therapeutics US INC. | $69.40 | 2023-2025 | Tarpeyo |
| Horizon Therapeutics Plc | $56.05 | 2021 | |
| Ani Pharmaceuticals, INC. | $55.03 | 2023-2024 | Purified Cortrophin Gel |
| Novo Nordisk INC | $50.10 | 2023-2025 | Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $46.32 | 2020-2022 | |
| Shire North American Group INC | $38.65 | 2019 | |
| Baxter Healthcare | $31.36 | 2019 | |
| Kyowa Kirin, INC. | $27.56 | 2023 | Crysvita |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.78 | 2025 | Jardiance |
| Ardelyx, INC. | $23.92 | 2025 | Ibsrela |
| Daiichi Sankyo INC. | $22.76 | 2023 | Injectafer |
| Apellis Pharmaceuticals, INC. | $22.56 | 2025 | Empaveli |
| Genzyme Corporation | $20.61 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $19.22 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $18.91 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manjula Naik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.